5-MeO-DiPT

Psychedelic tryptamine

5-MeO-DiPT, also known as 5-methoxy-N,N-diisopropyltryptamine and sometimes as foxy methoxy or simply foxy, is an atypical psychedelic drug of the tryptamine and 5-methoxytryptamine families. It has unique and distinct effects from other serotonergic tryptamines, including some stimulant- and entactogen-like effects, robust tactile and sexual enhancement, and only light hallucinogenic effects. The drug is usually taken orally, but may also be used by other routes.

It acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT1A and 5-HT2A receptors among others. Uniquely among most tryptamines, the drug has been found to produce serotonergic neurotoxicity and associated cognitive deficits in rodents reminiscent of but distinct from those observed with MDMA. Various severe and/or fatal intoxications associated with 5-MeO-DiPT have been reported in humans. It is the 5-methoxy derivative of diisopropyltryptamine (DiPT) and is an analogue of other psychedelic tryptamines like 4-HO-DiPT, 5-MeO-DMT, and 5-MeO-MiPT.

5-MeO-DiPT was first described in the literature by Alexander Shulgin and colleagues in 1980. Subsequently, Shulgin described 5-MeO-DiPT in further detail in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). The drug was first encountered as a novel designer drug in 1999. It is used recreationally as a "party drug" and sexual enhancer, with notable use among gay men and transgender women as part of "chemsex", although its use in general has declined over time and is rare. 5-MeO-DiPT became a controlled substance in the United States in 2003. The closely related drug 5-MeO-MiPT (moxy) has similar effects as 5-MeO-DiPT, remains legal in the United States and many other countries, and is often used as a substitute for 5-MeO-DiPT.